Endeavor BioMedicines Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference
Following are details about the Endeavor poster presentations at ATS 2025:
Title: Deep Learning-based Disease Severity Biomarkers on CT; Posthoc Analysis in a Phase 2a Placebo-controlled Study of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis
Abstract Session: C23 – On The Horizon: Imaging and Molecular Biomarkers in Fibrotic ILD
Presenter: Simon Walsh, M.D., Ph.D., Thoracic Radiologist, Qureight Ltd.
Date and Time:
Location: Room 2002/2004 (West Building, Level 2), Moscone Center
Title: WHISTLE-PF: Study Design of A Phase 2b, Multi-center, Randomized, Double-blind, Controlled Trial of ENV-101 (Taladegib) In Patients With Idiopathic Pulmonary Fibrosis
Abstract Session: A74 – Fibrotic Lung Disease Revisited
Presenter: Toby M. Maher, M.D., Ph.D., Professor of Medicine and Director of Interstitial Lung Disease at Keck School of Medicine, University of Southern California, Los Angeles
Date and Time: May 18, 2025, 9:15-4:15 p.m. PT
Location: Area G, Hall F, (North Building, Exhibition Level), Moscone Center
For more information about Endeavor BioMedicines and the company's activities at ATS 2025, visit https://endeavorbiomedicines.com/ats.
About Idiopathic Pulmonary Fibrosis
IPF is a chronic, progressive lung disease that affects more than 150,000 adults in the United States. Although the exact cause of IPF is unknown, various environmental factors can deliver repeated injuries to lung cells that trigger abnormal wound-healing processes and life-threatening lung scarring. IPF is a chronic disease with limited treatment options and a very poor prognosis: the average life expectancy is only three to five years after diagnosis.
About ENV-101
Endeavor BioMedicines' investigational medicine ENV-101 is a Hedgehog signaling pathway inhibitor. By binding to and inhibiting a key receptor in the Hedgehog pathway, ENV-101 stops the abnormal accumulation of the myofibroblasts that cause fibrosis. This may resolve the excessive wound-healing process seen in pulmonary fibrosis, improving lung volume and function.
About Endeavor BioMedicines
Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases. Endeavor's lead candidate, ENV-101 (taladegib), is an inhibitor of the Hedgehog signaling pathway in development for fibrotic lung diseases, including idiopathic pulmonary fibrosis (IPF). The company's second candidate, ENV-501, is a HER3 antibody-drug conjugate (ADC) in development for the treatment of HER3-positive solid tumors. More information is available at www.endeavorbiomedicines.com and on LinkedIn or X.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
7 minutes ago
- Business Wire
Life Sciences BC's 10th Annual Invest in BC Conference Connects Industry Leaders
VANCOUVER, British Columbia--(BUSINESS WIRE)--Life Sciences British Columbia (LSBC) is proud to present the 10th Annual Invest in BC, powered by Lumira Ventures, taking place October 28–29, 2025 at the Vancouver Convention Centre West. Celebrating a decade of impact, Invest in BC has become a cornerstone event for the province's thriving life sciences sector. It brings together investors, entrepreneurs, researchers, and industry leaders for two days of high-impact networking, strategic partnering, and investment exploration. Whether attending to pitch, partner, or learn, participants will find unparalleled opportunities to connect and collaborate. 'Invest in BC is where innovation meets opportunity,' said Wendy Hurlburt, President and CEO of Life Sciences BC. 'This event brings together the full spectrum of our ecosystem—from early-stage ventures to global industry leaders—to spark conversations, build relationships, and accelerate the future of health.' Event Highlights: 30+ companies pitching across Biotech, MedTech, and Digital Health Dedicated partnering sessions for one-on-one meetings Exhibitor booths showcasing cutting-edge industry solutions Panels featuring ecosystem thought leaders Networking to spark meaningful connections Companies Selected to Pitch Include: Arbutus Medical, ARC Medical, AVEE HEALTH, Bold Therapeutics, Careteam Technologies, eSense Health, Evolved Therapeutics, Eyam Health, EyecareX, GuideStar Medical Devices, HTuO Biosciences, Ikomed, ImageCyte Technologies, Integrated Nanotherapeutics, Kapoose Creek Bio, Molecular You, NZ Technologies, Optigo Biotherapeutics, Pramana Pharmaceuticals, Redwood AI, Reverb Therapeutics, Seragene Therapeutics, Sonic Incytes, Sonus Microsystems, Sustained Therapeutics, Total Flow Medical, Variational AI, Vesalius Cardiovascular, ViewsML Technologies, VoxCell BioInnovation, and Zymeworks. "British Columbia's world-leading life sciences and biomanufacturing ecosystem continues to thrive, with B.C. companies making lives better globally," said Ravi Kahlon, Minister of Jobs and Economic Growth. "As uncertainty and anti-science sentiment grow south of our borders, B.C. remains a stable, science-driven jurisdiction committed to life sciences research and commercialization. We're making it easier than ever for companies to do business in the province. I invite investors and entrepreneurs to join the momentum and grow their businesses in B.C." Thank You to Our Confirmed Supporters Invest in BC is made possible by the generous support of these organizations: Event Details: Dates Location: Vancouver Convention Centre West Secure Your Spot: Early registration available until September 26. For more information or to register, visit:
Business Wire
7 minutes ago
- Business Wire
Sonendo Strengthens Leadership Team With Promotion of John McGaugh to Chief Operating Officer
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Sonendo, Inc. ('Sonendo' or the 'Company') (OTC Pink: SONX), a leading dental technology company and developer of the GentleWave® System, today announced the promotion of John McGaugh to Chief Operating Officer. Mr. McGaugh previously held the position of Senior Vice President of Operations. 'Since Sonendo embarked on its strategic reset in early-2024, the Company has stabilized revenue, generated significant leverage in gross margin, and meaningfully lowered total operating expenses, adjusted EBITDA loss and cash burn,' stated Bjarne Bergheim, President and Chief Executive Officer of Sonendo. 'John has been a significant contributor to all those improvements, and we expect he will continue to drive additional operating leverage as the Company continues to execute its plans to achieve profitability. John is a valuable member of the team, and I am excited to see him take on the role of Chief Operating Officer.' In addition to his previous responsibilities overseeing quality, manufacturing, supply chain, and technical services operations, Mr. McGaugh now has oversight of Sonendo's capital and consumables sales teams and commercial operations. Mr. McGaugh has over 20 years overseeing global manufacturing operations. He joined Sonendo in May 2023 and has been instrumental in leading significant operational efficiencies with console assembly and procedure instrument margin contributions. Prior to his time at Sonendo, Mr. McGaugh served as a multi-site operational leader for Abbott Vascular. In addition to his experience at Abbott, Mr. McGaugh has held leadership roles at Boston Scientific and American Medical Systems. About Sonendo Sonendo is a commercial-stage medical technology Company focused on saving teeth from tooth decay, the most prevalent chronic disease globally. Sonendo develops and manufactures the GentleWave® System, an innovative technology platform designed to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The system utilizes a proprietary mechanism of action, which combines procedure fluid optimization, broad-spectrum acoustic energy and advanced fluid dynamics, to debride and disinfect deep regions of the complex root canal system in a less invasive procedure that preserves tooth structure. The clinical benefits of the GentleWave System when compared to conventional methods of root canal therapy include improved clinical outcomes, such as superior cleaning that is independent of root canal complexity and tooth anatomy, high and rapid rates of healing and minimal to no post-operative pain. In addition, the GentleWave System can improve the workflow and economics of dental practices. For more information about Sonendo and the GentleWave System, please visit To find a GentleWave doctor in your area, please visit Forward Looking Statements This news release includes forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the Company's ability to continue to drive additional operating leverage and/or execute its plans to achieve profitability, whether as a result of Mr. McGaugh or otherwise. You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions; speak only as of the date they are made; and, as a result, are subject to risks and uncertainties that may change at any time. Factors that could cause the Company's actual results to differ materially from these forward-looking statements are described in detail in the 'Risk Factors' section of the Company's Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on March 26, 2025. Such filings are available at The Company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent developments, events, or circumstances, except as may be required under applicable securities laws. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
Business Wire
7 minutes ago
- Business Wire
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in September: Citi's 2025 Biotech Back to School Conference Date: Wednesday, September 3 rd, 2025 Location: Boston, MA Format: Fireside chat & 1x1 meetings Time: 11:15 a.m. ET H.C. Wainwright 27 th Annual Global Investment Conference Date: Tuesday, September 9 th, 2025 Location: New York, NY Format: Fireside chat & 1x1 meetings Time: 8:00 a.m. ET Morgan Stanley 23 rd Annual Global Healthcare Conference Date: Wednesday, September 10 th, 2025 Location: New York, NY Format: Fireside chat & 1x1 meetings Time: 8:30 a.m. ET Live webcasts of the fireside chats will be available by visiting the 'Investors & Media' section of the Arcus Biosciences website at Replays will be available following the live event. About Arcus Biosciences Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- and/or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into registrational clinical trials including domvanalimab, an Fc-silent anti-TIGIT antibody being studied in combination with zimberelimab, an anti-PD-1 antibody, for upper gastrointestinal and non-small cell lung cancer, casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. For more information about Arcus Biosciences' clinical and preclinical programs, please visit
